---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005403"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:04:53.326012+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology Q2 loss $0.22/share; revenue $2.7K; ChemoFx U.S./EU launch expected Q4 2025

## Summary
- Loss from continuing ops ~$2.0M; diluted EPS -$0.22 vs -$0.53 YoY.
- Revenue $2,682, down 96% from $67,255 due to lower 3D model sales.
- Cash $506K; stockholders' deficit $1.65M vs $202K at Dec 31, 2024.
- Signed $10M standby equity purchase agreement with Yorkville Advisors.
- Advanced ChemoFx market expansion; developed 3D liver models for Labcorp.

## SEC filing metadata
- accession: 0001171843-25-005403
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184325005403/0001171843-25-005403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184325005403/f8k_081325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005403
- JSON: https://secwatch.observer/filing/0001171843-25-005403.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.